Akston Biosciences CEO and leadership

Todd C. Zion, Ph.D. founded SmartCells, Inc. in 2003 to develop SmartInsulin™, the first glucose-regulated, injectable formulation for treating diabetes. As SmartCells’ President and CEO, Todd was instrumental in raising $10M in equity financing from individual investors and $10M in grants to support research and clinical development. In December 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments.

Dr. Zion developed the SmartInsulin™ technology as part of his doctoral thesis work in Chemical Engineering at the Massachusetts Institute of Technology. Prior to enrolling at MIT, he worked as a polymer development engineer at Eastman Kodak. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering.

Dr. Zion now enjoys advising technology entrepreneurs through MIT’s Venture Mentoring Service. He also serves on a number of advisory boards including those of the Beth Israel Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering College Council.

Todd C. Zion, Ph.D. founded SmartCells, Inc. in 2003 to develop SmartInsulin™, the first glucose-regulated, injectable formulation for treating diabetes. As SmartCells’ President and CEO, Todd was instrumental in raising $10M in equity financing from individual investors and $10M in grants to support research and clinical development. In December 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments.

Dr. Zion developed the SmartInsulin™ technology as part of his doctoral thesis work in Chemical Engineering at the Massachusetts Institute of Technology. Prior to enrolling at MIT, he worked as a polymer development engineer at Eastman Kodak. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering.

Dr. Zion now enjoys advising technology entrepreneurs through MIT’s Venture Mentoring Service. He also serves on a number of advisory boards including those of the Beth Israel Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering College Council.

Todd C. Zion, Ph.D. founded SmartCells, Inc. in 2003 to develop SmartInsulin™, the first glucose-regulated, injectable formulation for treating diabetes. As SmartCells’ President and CEO, Todd was instrumental in raising $10M in equity financing from individual investors and $10M in grants to support research and clinical development. In December 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments.

Dr. Zion developed the SmartInsulin™ technology as part of his doctoral thesis work in Chemical Engineering at the Massachusetts Institute of Technology. Prior to enrolling at MIT, he worked as a polymer development engineer at Eastman Kodak. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering.

Dr. Zion now enjoys advising technology entrepreneurs through MIT’s Venture Mentoring Service. He also serves on a number of advisory boards including those of the Beth Israel Deaconess Medical Center, Joslin Diabetes Center, and the Cornell Engineering College Council.